Kytopen’s Post

📍 Prediction of patient response using single-cell transcriptomics Sinha et al. developed PERCEPTION, a computational pipeline for systematically predicting patient response to cancer drugs at single-cell (sc) resolution. Key points ☑️ Using publicly available matched bulk and sc expression profiles from large-scale cell-line drug screens ☑️ Building treatment response models based on patients’ sc-tumor transcriptomics ☑️ Predicting responses to targeted therapies in cultured, patient-tumor-derived primary cells, and clinical trials ☑️ Capturing the resistance development in cancer therapy with tyrosine kinase inhibitors ☑️ Outperforming state-of-the-art sc-based and bulk-based predictors ☑️ Access at https://lnkd.in/ehEPja9y. More details: https://lnkd.in/ekp5CpSC #Nationalcancerinstitute #spatialomics #spatialbiology #singlecellanalysis #singlecell

Emergence of ADCs as the “Hot, New Technology” The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to antibody-drug conjugates (ADCs), highlighting their potential in cancer therapy. This development serves as an opportunity for companies to reflect on the progress within the ADC field and consider its implications for the future of cell therapies. In this article, I provide a brief overview of the history of ADCs, exploring their evolution and what they can teach us about advancing cancer treatments. The aim is to offer insights into the challenges and opportunities that lie ahead for ADCs and cell therapies, shedding light on lessons that may shape the cell therapy space. https://lnkd.in/gMFKyz_3 #aspenalert #biotech #bioprocess

Antibody avidity meets multiple myeloma ABSTRACT In the ongoing search for innovative treatments to combat refractory and relapsed cancer, new preclinical work in multiple myeloma shows that increasing binding avidity by targeting two antigens in one T cell-engaging trispecific antibody boosts anti-tumor activity and reduces the likelihood of tumor escape relative to current antibody-based therapies. PAPER: https://lnkd.in/d_FWm5Y4

🎗 World Lung Cancer Day: 1 August 🫁 🫁 Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women! 🫁 It's believed that on-chip technologies, particularly Organ-on-Chip (OoC) and Tumor-on-Chip (ToC), offer significant advancements in the diagnosis, drug discovery, and development processes for lung cancer. 🫁 Here are the primary challenges in lung cancer research that can be tackled using on-chip technologies: 1️⃣ Lack of Accurate Disease Models 2️⃣ High Failure Rates in Drug Development 3️⃣ Ethical and Regulatory Issues 4️⃣ High Costs and Long Timelines 5️⃣ Limited Personalized Medicine Approaches 6️⃣ Ineffective Toxicity Prediction #cancer #tumor #oncology #microfluidics #onchip #chiptechnology #TumorOnChip #CancerOnChip #OrganOnChip #drugdiscovery #drugdevelopment #biotechnology #biomedicalresearch #pharmaceuticalindustry

SIRPα is a transmembrane protein predominantly expressed on myeloid cells. It interacts with CD47, a protein often referred to as the "don't eat me" signal, which is expressed on the surface of various cells, including cancer cells. This interaction inhibits the phagocytosis of cells by macrophages, allowing cancer cells to evade the immune system. Current methods for assessing the activity of SIRPα/CD47 checkpoint inhibitors rely on primary monocyte-derived macrophages and direct measurement of phagocytosis. These assays are laborious and highly variable due to their reliance on donor cells, complex assay protocols and unqualified assay reagents. #Promega 's SIRPα/CD47 Blockade Bioassay is a bioluminescent reporter cell-based assay designed to measure potency and stability of Biologics that bind and block SIRPα/CD47 interactions without the need of cultured primary cells, providing significant time and labor savings. More at: https://lnkd.in/eE_yAkH5 #SIRPα/CD47 #Bioassays #potency Promega Switzerland

Accelerate cancer therapy development with Promega's advanced bioassay technology! CD47/SIRPα interaction is an example of immune checkpoint, where myeloid cells evade T cell activity. Preclinical studies are developing molecules that are able to block CD47-SIRPα interactions and lead to targeted tumor killing. Thanks to the powerful Nanoluc® reporter, Promega released specific cell-based bioassays for the assessment of potency and stability of Biologics blocking the interaction. Read more at: https://lnkd.in/ekRYR4Z7

If you’re developing an antibody-drug conjugate (ADC) to treat cancer, you need data-backed answers to these questions: -Is the antibody being internalized? -Where’s the therapeutic trafficked? -Is the drug actually killing cancer cells? And that’s where imaging and bioassays come in. Through a suite of imaging assays, our team of scientists can help you select your lead candidates from hundreds to a handful, making sure that the best candidate progresses to IND filing. We can provide real-time data on internalization, trafficking, tumor-cell killing, and a host of other cell functions. All of these powerful imaging assays and analyses come early on in the development process because we believe in starting smart, so you can progress fast to IND and beyond. Find out more about our assay capabilities here: https://lnkd.in/ez2YMCCD #microscopy #drugdevelopment #CDMO #CRO #ADCCDMO

Delve into the molecular intricacies of cancer with DRUG-seq, an affordable and efficient RNA-seq application that is changing the landscape of oncology drug discovery. This state-of-the-art technology drives innovation in investigating mechanisms of drug action, profiling drug responses, discovering biomarkers, and untangling tumor heterogeneity. Contact us to find out how you can use Champions' new DRUG-seq platform to generate fast insights in drug discovery. https://hubs.li/Q02pvCkq0 #DRUGseq #OncologyResearch #CancerResearch #RNAseq #MechanismOfAction #DrugResponse #DrugResistance #BiomarkerDiscovery #TumorHeterogeneity #Oncology #Cancer #PrecisionMedicine #DrugDiscovery #endpointspotlight

Delve into the molecular intricacies of cancer with DRUG-seq, an affordable and efficient RNA-seq application that is changing the landscape of oncology drug discovery. This state-of-the-art technology drives innovation in investigating mechanisms of drug action, profiling drug responses, discovering biomarkers, and untangling tumor heterogeneity. Contact us to find out how you can use Champions' new DRUG-seq platform to generate fast insights in drug discovery: https://hubs.li/Q02HsjHk0 #DRUGseq #OncologyResearch #CancerResearch #RNAseq #MechanismOfAction #DrugResponse #DrugResistance #BiomarkerDiscovery #TumorHeterogeneity #Oncology #Cancer #PrecisionMedicine #DrugDiscovery #endpointspotlight

Exosomes, nanosized vesicles released from cells, are gaining popularity as drug delivery vehicles due to their ability to escape liver homing and undesired accumulation. Bovine milk/colostrum-derived exosomes, functionalized for cancer therapeutics, show promise, including validation of anti-tumor efficacy. Check out this free webinar by our friends at Spectral Instruments Imaging on June 11, at 10 AM PDT (12 PM CDT / 1 PM EDT), and learn how milk exosomes can be utilized for targeted drug delivery & the latest advancements in RNA & DNA delivery using the Exosome-PEI-Matrix (EPM) technology: https://lnkd.in/dbPmmX-y #Oncology #Exosomes #Milk #Imaging #PreclinicalImaging